Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Inclusion Criteria: * recurrent or persistent vulvar Paget's disease with overexpression of HER2 by immunohistochemistry and or fluorescence in situ hybridization (FISH) * Biopsy for histologic confirmation * Measurable disease * Karnofsky score of 50-100 * recovered from effects of recent surgery, radiotherapy, or chemotherapy * free of active infection requiring antibiotics * adequate bone marrow function,renal function,hepatic function,cardiac function,WOCBP-neg.serum pregnancy,meet requirements in section 7.0 Exclusion Criteria: * no measurable disease * tumors not HER2 positive by immunohistochemistry FISH * prior therapy with any anti-HER2 monoclonal antibody preparation * Karnofsky score of 0-40 * other invasive malignancies, with the exception of non-melanoma skin cancer * Patients requiring supplemental oxygen * unstable medical conditions in the opinion of the treating physician place them at unacceptably increased risk from trastuzumab therapy * Patients with active or unstable cardiac disease, or myocardial infarction within 6 months